The clinical value of PSA for prostate cancer early detection has been questioned primarily due to its poor specificity for clinically relevant disease, namely high grade prostate cancer. This is especially true at PSA levels lower than 4 ng/mL, generally considered to be within the normal range. However, PSA values between 1.5-4 ng/mL have been referred to as the PSA Danger Zone because the risk of prostate cancer in men with PSA within this range is 15-18x higher compared to that in men with PSA< 1.5ng/mL. Moreover, a surprising number of otherwise healthy men with PSA less than 4 ng/mL are at risk for prostate cancer metastases and death up to 20 years later. The 4Kscore Test has been validated to predict an individual man's risk of high grade cancer on biopsy, with an area under the curve of 0.82. This test incorporates: Total PSA (tPSA), Free PSA, Intact PSA, human Kallikrein-2, age, digital rectal examination findings, and previous biopsy information into an algorithm. The objective of this study was to see if the 4Kscore Test can predict high grade (Gleason ≥ 7) prostate cancer in men with a tPSA < 4 ng/mL.
Introduction: Prostate cancer (PCa) is the most common solid tumor in men. Active surveillance (AS) is an acceptable alternative to immediate treatment for low-risk, Gleason pattern 3 (GP3) PCa. Furthermore, recent reports from Klotz et al in Toronto have demonstrated the outcomes of both intermediate risk, Gleason sum 7, and low risk Gleason 6 PCa in men on AS. Importantly men with intermediate risk fare significantly worse on AS. AS often entails significant risk of under-grading the tumor and repeated biopsies. We hypothesized that transcripts associated with high Gleason grade cancers are quantifiable in urine samples and reflect the presence of higher-grade non-indolent tumors. Our objective was to develop a qPCR-urine-based assay for the detection of occult high-grade cancer GP4 Vs. GP3 disease, in urine samples from men diagnosed with PCa.
Methods:
We performed a prospective IRB approved evaluation of 53 men undergoing radical prostatectomy (RP) for clinically localized disease. In the operating room prior to RP men underwent a digital rectal exam (DRE) followed by collection of urine by catheterization. Final pathology reviewed by a single GU pathologist was used as the gold standard for determination of final histological Grade. We had previously identified 4 consistently up-regulated GP4 transcripts (RELN, GRIN3A, RGS5 and LRNN1) Quantitative PCR (qPCR) was performed for the GP4 markers and normalized to KLK3 and RPL13A. By comparing transcriptional profiles of GP3 and GP4 cancers, we identified transcripts differentially expressed between these histologies. To evaluate the ability of the GP4 markers to discriminate between low and high-grade tumors, univariate and multivariate logistic regression analyses were performed and the overall significance determined using likelihood ratio tests.
Results:
Each gene was an independent predictor of high-grade (Gleason score ≥4+3 vs. ≤3+4) prostate cancer (p<0.05 for each gene) with area under receiver operating characteristic curves (AUC) of 0.786, 0.770, 0.794, and 0.784. When tested as a panel, the 4 genes were significantly associated with high-grade cancer (Primary pattern Gleason 4 disease) based on the overall likelihood ratio test (p=0.002). Furthermore, the 4-gene panel outperformed each gene alone, with an AUC of 0.841.
Conclusions:
A novel 4-gene panel assayed by qPCR in men undergoing RP appears to be capable of discriminating clinically relevant high-grade (Gleason≥4+3) tumors from low-grade (Gleason≤3+4) tumors using urine sediments. Further studies are needed to confirm these preliminary findings. DoD W81XWH-13-1-0050 / PC110970 CCSG: 5 P30 CA0154704 RO1: 1 R01 CA181605 Healthcare Partners and each service was translated into a CPT code in the year the service was performed. The CMS fee schedule was used to translate this information into a cost via the global allowable amount. Hospital inpatient costs were calculated according to published base rates from the Federal Register multiplied by the weights of the associated Diagnosis Related Groups on the CMS website and co-morbidities were determined according to diagnoses present in each patient's chart.
Results:
The average cost incurred over a three year period for the AS patients (n = 20) was $4,292.61 (sd = 1,846.78), for RT patients (n = 22) was $50,337.90 (sd = 8,691.01) and for RP patients (n = 27) was $10,466.83 (sd = 2,129.67). The average cost incurred over a three year period for AS patients who progressed and received RT (n=5) was $44,955.56 (sd = 12,704.56) or received RP (n = 1) was $12,615.80.
Conclusions:
Active Surveillance is considered an appropriate management strategy for low risk PCa patients mitigating the potential complications associated with both surgery and radiation treatment. Our preliminary analysis comparing costs for all 3 management options suggest that AS has a significant cost benefit as well. Active Surveillance management of patients with low risk PCa may be considered desirable from a value (quality/cost) based perspective. Objective: Morcellation is the most common method of tissue retrieval following Holmium laser enucleation of the prostate (HoLEP). This study compares the morcellation efficiency of the Wolf® Piranha™ to the Lumenis® VersaCut™.
MORCELLATION EFFICIENCY IN HOLMIUM LASER ENUCLEATION OF THE PROSTATE: WOLF PIRANHA OUTPERFORMS LUMENIS VERSACUT WITH NO APPARENT LEARNING CURVE
Methods: After IRB approval, we conducted a retrospective analysis of patients undergoing HoLEP for symptomatic benign prostatic hyperplasia. All surgeries were performed by MRH at Mayo Clinic Arizona (MCA). The first 41 cases of HoLEP with morcellation performed with the Piranha at MCA were matched by weight of resected tissue to 41 control patients from our historic data set that underwent morcellation with the VersaCut. The primary outcome of interest was morcellation efficiency. Patient demographics and intraoperative and postoperative data for patients in the two cohorts were compared. We also evaluated the morcellation efficiency of the Piranha compared to number of cases performed, along with impact of trainee involvement to assess for a learning curve. Wilcoxon rank sum test and Fischer's exact test were utilized.
Results:
The 41 patients from each group were comparable in terms of age, prostate size, continuation of aspirin, and catheter status (Table) . The Piranha morcellation efficiency was nearly double that of the VersaCut [8.6 g/min (range 3.0-18.3) vs 3.8 g/min (range 0.9-10.1), p<0.0001]. Mean resected weight for cases with the Piranha and VersaCut was 69g (range 17-224g) and 69g (range 17-213g) respectively (p=0.9). The total operative time and complication rates did not significantly differ. For the Piranha, morcellation efficiency for cases performed by MRH alone was 9.8 g/m compared to 8.1 g/min when trainees were involved (p=0.2), and there was no correlation between morcellation efficiency and number of cases performed (R=0.01).
Conclusions:
The Piranha system resulted in a morcellation efficiency that was double that of the VersaCut for tissue retrieval after HoLEP. Achieving efficiency with the Piranha system was not associated with a significant learning curve and was not impacted by trainee involvement. Methods: A retrospective analysis of 157 patients who underwent TUMT at a single Veterans Affairs facility for treatment of benign prostatic hyperplasia was completed. The primary efficacy variable was success in catheter removal. We recorded time of follow up, types of anticoagulation, prostate size, time to patient death, and number of UTIs a year prior and a year post procedure. Additionaly, we analyzed post-procedural complications, including bleeding events.
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THE SAFETY AND EFFICACY OF TRANSURETHRAL MICROWAVE THERAPY IN HIGH-RISK CATHETER DEPENDENT MEN AT A SINGLE VETERANS AFFAIRS CENTER
Results: Prior to treatment 105 men were in urinary retention (requiring an indwelling urethral catheter or clean intermittent catheterization). The mean age was 76.9 (95% CI 74.9 -78.8) and median ASA-score was 3. At a median follow up of 26 months (range 1 -65), 63.7% remained free from the need for indwelling or intermittent catheterization. Of the treated patients, 38% (40/105) died due to unrelated causes during the follow up period. Treatment failure was not associated with an increased risk of death when compared to Kaplan-Meier Survival Estimate. Surprisingly, prostate size was inversely associated with postoperative retention (mean prostate volume 60.6 ml vs 42.9 ml, p<0.04). No significant predictor of success was found on multivariate analysis. Overall, 86% of patients underwent TUMT while on anticoagulant therapy. 25% of all treated patients were treated while taking warfarin. Only two men experienced hematuria requiring treatment postoperatively. No transfusions were required. The 30-day postoperative complication rate was low, with readmission required in only 2 patients (1.9%).
Conclusions: Our results demonstrate TUMT is a safe and efficacious therapeutic option for high-risk catheter dependent men. Furthermore, the low incidence of adverse bleeding events suggests that TUMT is a safe treatment modality for men undergoing anticoagulation therapy. The inverse relationship of prostate volume with catheter independence suggests nonobstructive causes of retention in TUMT failures. Introduction: Prostate cancer (PCa) is the leading form of cancer in men with an estimated lifetime risk of 1 in 6 men per the American Cancer Society; however, it remains the only solid organ that utilizes a standardized, systematic approach to sampling without incorporating direct visualization or radiographic imaging to locate areas of interest. Fortunately, multi-parametric MRI (MP-MRI) has emerged as a useful adjunct to increase cancer detection rates (CDR) by affording increased resolution, functional assessment, and superior imaging of anatomical structures. MP-MRI in conjunction with an MRI-US fusion guided biopsy (bx) has demonstrated not only improved PCa detection, but most importantly clinically significant disease. Unfortunately, this technology has been limited to tertiary care centers; therefore, we sought to compare cognitive versus targeted software based CDR to assess its ability to disseminate more readily into the community.
Source of Funding: None
UTILITY OF MULTI-PARAMETRIC MRI/ULTRASOUND FUSION: COGNITIVE NOT INFERIOR TO TARGETED SOFTWARE-BASED PROSTATE BIOPSIES
Material and Methods:
Consecutive patients underwent an MRI-US fusion prostate bx for elevated PSA, abnormal DRE, or prior negative bx with a persistently elevated PSA. All subjects underwent pre-bx MP-MRI and lesions visible on MRI were graded using the PI-RADS version 2 classification system by a team of GU radiologists. The UroNav bx tracking system was used to fuse the stored MR images with real-time ultrasound generating a 3D model, which was then used to sequentially perform cognitive, targeted, and standard 12 core systematic biopsies in an office setting under local anesthesia. Descriptive statistics included patient characteristics and univariate analysis was done using logistic regression analysis to detect the associations between presence of cancer, clinically significant cancer, demographic variables, and bx method. The signed rank test was used for paired comparisons amongst bx method.
Results: A total of 37 patients (median age 66 yrs, median PSA 6.3) underwent an MRI-US fusion bx between July 2014 and October 2015 with an overall CDR of 59%. Cognitive CDR was 40.5% compared to targeted CDR of 24.3%. Overall, the cognitive approach had a sensitivity of 68.2% (95% CI: 45%, 86%) where as the targeted approach captured the fewest cancers with a sensitivity of 40.1% (95% CI: 21%, 64%). Furthermore, the targeted approach missed 7 cancers when compared to the cognitive approach, whereas, the cognitive approach only missed 1 cancer when compared to the targeted approach. Of note, the difference in sensitivity is most pronounced when comparing standard and targeted methods (p=0.04) and approaches significance when comparing cognitive and targeted methods (p=0.07).
Conclusion: MRI-US fusion targeted software has been associated with high detection of both PCa and clinically significant disease, however, when compared to the cognitive platform, it was not found to have higher CDR nor sensitivity, which likely highlights the importance of the MRI itself, rather than the platform used, which further supports its ability to disseminate more readily into clinical practice.
